A New Chemiluminescent Enzyme Immunoassay for Plasma Tissue Factor Detection

Yuki Fujiwara¹,², Yoshikatsu Koga¹, Kimiko Hasegawa¹, Hiroya Fujii¹, Tetsuji Yamaguchi¹, Ryou Tsumura¹,², Masahiro Yasunaga¹ and Yasuhiro Matsumura¹,²*

¹Division of Developmental Therapeutics, Research Centre for Innovative Oncology, National Cancer Centre Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
²Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa, Chiba, Japan
³JSR Life Sciences, R&D Department Unit 1, 25 Miyukigaoka, Tsukuba, Ibaraki, Japan

Abstract

High concentrations of tissue factor (TF) in the plasma may have a major role in the elevated risk of thrombosis in patients with malignant diseases. The quantification of plasma TF concentrations in cancer patients may enable accurate assessments of the risk of thrombosis during the process of cancer progression. Whether the plasma TF concentration is associated with the tumor volume in pancreatic cancer remains uncertain. Rat anti-human TF monoclonal antibodies were prepared in our laboratory and were used in a chemiluminescent enzyme immunoassay (CLEIA) for TF detection. In an in vitro experiment, the antibodies for human TF did not cross-react with mouse TF. Therefore, tumor-derived TF was specifically detected using a novel sensitive human TF detection system developed for this study. The plasma concentration of tumor-derived TF was positively correlated with the tumor volume in mice bearing the human pancreatic cancer cell line BxPC-3. Thus, the plasma TF concentration may be a useful tumor marker. These data warrant further preclinical and clinical investigations of our CLEIA system.

Keywords: Pancreatic cancer; Tumor marker; Tissue Factor (TF); Chemiluminescent Enzyme Immunoassay (CLEIA)

Introduction

Ever since Armand Trousseau reported thrombophlebitis as a complication of cancer in the 19th century, an association between cancer and hyper coagulability has been generally accepted [1,2]. Tissue factor (TF), a 47-kDa trans membrane glycoprotein, is essential for blood coagulation. TF is known to be over expressed not only on tumor cells but also on tumor stromal cells including tumor vascular endothelial cells in various human tumor tissues [3,4]. Thus, the high plasma concentration of TF observed in patients with malignant diseases may have a major role in the elevated risk of thrombosis in these patients. The quantification of plasma TF-bearing micro particles in cancer patients may enable an accurate assessment of the risk of thrombosis during the process of cancer progression [5]. Pancreatic cancer patients have a strong likelihood of developing cancer-associated thrombosis, compared with healthy volunteers [6]. However, whether the plasma TF concentration is associated with the tumor volume in patients with pancreatic cancer remains uncertain in the field of cancer biology.

In this context, we have constructed a new chemiluminescent enzyme immunoassay (CLEIA) using an anti-human TF monoclonal antibody that we developed [7]. The CLEIA automated system is known to be more effective than conventional systems, such as enzyme-linked immune sorbent assay (ELISA) [8]. Therefore, the plasma TF concentrations before and after tumor resection were evaluated in mice bearing BxPC-3 subcutaneous tumors using our CLEIA system.

Materials and Methods

Cell lines

The human pancreatic cancer cell lines BxPC-3 and MIA PaCa-2 (TF-negative cells [7]) were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Wako, Osaka, Japan) with incubation at 37°C in a humidified atmosphere containing 5% CO₂.

Antibodies and proteins

Recombinant human and mouse TF proteins, which are the extracellular domains of human and mouse TF without the signal peptide, were obtained using conventional synthesizing methods and Escherichia coli. Recombinant human TF was used to make the calibration curve. The anti-human TF monoclonal antibody (mAb)-producing hybridoma clones 1849 and 1006 were established in our laboratory [7].

Western blotting analysis

Horseradish per oxidase (HRP)-labeled anti-human TF 1849 mAb was prepared using Per oxidase Labeling Kit-NH₂ (DOJINDO Molecular Technologies, Kumamoto, Japan), according to the manufacturer’s instructions. The BxPC-3 cells and tumor tissues were lysed in whole extraction buffer (20 mM HEPES-NaOH, 0.5% NP-40, 15% glycerol) with a protease inhibitor cocktail (Roche Diagnostics). The proteins (tumor lysate and plasma) were immune precipitated using anti-human TF immune beads. The proteins were separated using sodium do decyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and heat-shocked conditions, and then electrophoretically transferred to polyvinylidenedifluoride membranes (Bio-Rad, Hercules, CA, USA) using the Trans-Blot Turbo transfer machine (Bio-Rad). The membranes were blocked overnight at

Received October 23, 2014; Accepted November 26, 2014; Published December 03, 2014


Copyright: © 2014 Fujiwara Y et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
samples were then stored at -80°C until use. Plasma was separated from the mouse tail vein into 500-μL tubes containing heparin sodium. Blood was collected for TF detection. Magnosphere MS300/Carboxyl (JSR Life Sciences) was used according to the manufacturer’s instructions. Anti-human TF immune beads as a capturing antibody (0.05%, 50 μL) and samples (100 μL, conditioned media and plasma) were added to a 96-well flat-bottom white polystyrene plate (Corning, NY, USA) and then the samples were incubated for 30 min at room temperature. Only the plasma samples were diluted 20 times with Can Get Signal solution 1 (TOYOBO, Osaka, Japan) to minimize non-specific binding. The samples were then washed with Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) using Micro plate Washer Hydro Flex (Wako) and incubated with 100 μL of HRP-labeled anti-human TF 1006 mAb (1.0 mg/mL) as the detecting antibody for TF detection. Magnosphere MS300/Carboxyl (JSR Life Sciences) was added to a 96-well flat-bottom white polystyrene plate (Corning, NY, USA) and then the samples were incubated for 30 min at room temperature. Only the plasma samples were diluted 20 times with Can Get Signal solution 1 (TOYOBO, Osaka, Japan) to minimize non-specific binding.

Commercially available ELISA kit for TF detection

The ELISA kit was purchased from Assay Pro (MO, USA) and was used according to the manufacturer’s instructions. The sensitivity of this kit was compared with our CLEIA method described below.

CLEIA for TF detection

A novel immune bead was used to establish our CLEIA system for TF detection. Magnosphere MS300/Carboxyl (JSR Life Sciences) was conjugated with anti-human TF 1849 mAb (anti-human TF immune beads). Horseradish peroxidase (HRP)-labeled anti-human TF 1006 mAb was then prepared using Peroxidase Labeling Kit-NH2 (DOJINDO Molecular Technologies), according to the manufacturer’s instructions. Anti-human TF immune beads as a capturing antibody (0.05%, 50 μL) and samples (100 μL, conditioned media and plasma) were added to a 96-well flat-bottom white polystyrene plate (Corning, NY, USA) and then the samples were incubated for 30 min at room temperature. The subcutaneous tumors were usually detectable by 10 days after tumor cell inoculation and were resected on day 30. The tumor volume was calculated as (L×W³)/2. At 30 days after inoculation with the BxPC-3 cells, the tumor tissues were removed surgically. Blood was collected from the mouse tail vein into 500-μL tubes containing heparin sodium (Fuso Pharmaceutical Industries, Osaka, Japan). Plasma was separated from the blood by centrifugation at 2000g for 5 min. The plasma samples were then stored at -80°C until use.

Statistical analysis

Data are expressed as mean ± standard deviation (SD). All the results were statistically analyzed using Statcal QC software (The Publisher OMS, Saitama, Japan). A comparison of the TF values between the MIA PaCa-2- and BxPC-3-conditioned media was performed using a single-measure, simple-factorial ANOVA, followed by Student test. The chi-square test and the Spearman correlation coefficient were used to determine the significance of the associations between the plasma TF levels and the BxPC-3 tumor volume. A value of P < 0.05 was considered statistically significant.

Results

The specificity of anti-human TF 1849 mAb was clearly shown by the western blotting analysis (Figure 1A). In a commercially available ELISA kit, both the TF protein in the kit and our recombinant human TF protein produced a similar calibration curves (Figure 1B). The detection limit of the ELISA kit was 200 pg/mL (Figure 1B). Our CLEIA did not cross-react with mouse TF protein (Figure 1C).

To determine the sensitivity of CLEIA, a low concentration of recombinant human TF was used. The detection limit of the CLEIA method was determined to be 1.0 pg/mL (Figure 1D). The CLEIA system had a higher sensitivity than the ELISA kit. In addition, the ELISA system appeared to exhibit cross-reactivity against mouse TF (Table 1). Therefore, only the CLEIA system was used in subsequent analyses.

TF was detected in the BxPC-3 cell lysate using a western blotting analysis. However, the released TF could not be detected in the conditioned medium of the BxPC-3 cells, probably because the western blotting analysis used in this study was not sufficiently sensitive (Figure 2A). Therefore, CLEIA was used to detect the released TF from the tumor cells in the conditioned medium of BxPC-3. This assay revealed a significantly higher level of TF in the conditioned medium of the BxPC-3 cells than that in the conditioned medium of the TF-negative MIA PaCa-2 cells (Figure 2B), (P = 0.003).

The subcutaneous tumors were usually detectable by 10 days after tumor cell inoculation and were resected on day 30. The tumor volume was 98.1 ± 130 mm³ (mean ± SD) at 10 days, 524 ± 472 mm³ at 20 days, and 1719 ± 1046 mm³ at 30 days after tumor cell inoculation (Figure 3A). The plasma TF level was 33.1 ± 38.6 pg/mL (means ± SD) at 10 days, 53.5 ± 26.4 pg/mL at 20 days and 195 ± 54.5 pg/mL at 30 days after tumor cell inoculation (Figure 3B). The plasma TF level also decreased markedly after tumor resection: the plasma TF level was 67.5 ± 4.21 pg/mL at 10 days after resection and 37.6 ± 8.62 pg/mL at 20 days after resection, as determined using CLEIA (Figure 3B). The plasma TF level was positively correlated with the tumor volume (Figure 3C), rs = 0.61, P = 0.003. TF was detected in the tumor lysate and plasma of the tumor-bearing mice. The molecular weight of the TF detected from the tumor lysate was 47-kDa. In addition, the TF detected in the plasma of the tumor-bearing mice (C) had a molecular weight of 47-kDa (Figure 3D). Meanwhile, the TF was not detected in the plasma of normal mice (N).

Discussion

This study clearly showed that the sensitivity of CLEIA was superior to that of the commercially available ELISA kit. In addition, CLEIA appeared to be a simple and quick method. These features suggest that CLEIA could be a major tool for protein detection systems. Recently, a relationship between the tumor-derived plasma TF concentration and blood coagulation has been reported in mouse xenograft models of human pancreatic cancer [9]. Unfortunately to date, an association between tumor-derived TF and tumor volume has not been shown. In this study, we established CLEIA as a TF detection system with a sensitivity sufficient to distinguish changes in
(a) Western blotting was concentration-dependent for recombinant human TF from 0.25 mg/mL to 0.01 mg/mL.
(b) The lowest detection limit of the ELISA kits was 200 pg/mL. The recombinant human TF produced by our lab was used as a standard protein for human TF, since the recombinant human TF was concentration-dependent.
(c) CLEIA for high concentrations of TF proteins. The sensitivity and specificity of the CLEIA TF detection system were determined based on the reactivity for recombinant human TF and the cross-reactivity for recombinant mouse TF.
(d) CLEIA for low concentrations of TF proteins. The lowest limit of TF protein detection by CLEIA was 1.0 pg/mL.

Figure 1: Sensitivity and specificity of anti-human TFmAb.

<table>
<thead>
<tr>
<th>system</th>
<th>detection</th>
<th>Primary antibody</th>
<th>Secondary body</th>
<th>Detection limit</th>
<th>Crossreactivity against mouse TF</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA kit</td>
<td>Sandwich</td>
<td>Absorbance</td>
<td>Polyclonal</td>
<td>200 pg/mL</td>
<td>+</td>
</tr>
<tr>
<td>CLEIA (our lab)</td>
<td>Sandwich</td>
<td>Chemi-luminescence</td>
<td>Monoclonal</td>
<td>1.0 pg/mL</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 1: Enzyme immunoassay for TF

(a) Western blot analysis for TF in conditioned medium (CM) and cell lysate (CL). Released TF could not be detected in the conditioned medium of BxPC-3 cells, presumably because the western blot analysis used in this study was not sufficiently sensitive.
(b) The level of TF protein in the BxPC-3 CM was significantly higher than that in the MIA PaCa-2 CM, as measured using CLEIA (P = 0.003).

Figure 2: Level of TF in human pancreatic cell lines.
the plasma TF concentration reflecting tiny variations in the tumor volume. Plasma TF-bearing micro particles may leak from the tumor tissue into the circulation (Figure 3E). This study clearly showed that the plasma TF level was positively and significantly correlated with the tumor volume. When the tumor was completely resected, plasma TF gradually decreased. Plasma TF-bearing microparticle could remain in the blood for several days.

Since the plasma level of tumor-derived TF was positively correlated with the tumor volume, the plasma TF concentration may be a useful tumor marker. Furthermore, CLEIA may help to elucidate the influence of plasma TF on cancer progression.

Acknowledgement

This work was supported by the National Cancer Centre Research and Development Fund (Yasuhiro Matsumura, Y.M.), and the Funding Program for World-Leading Innovative R&D in Science and Technology (FIRST Program) (Y.M.).

References


Figure 3: Relationship between the tumor volume and the plasma TF concentration.